# US 2003/0083246 A1 · Methods for treating rheumatic diseases using a soluble CTLA4 molecule

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083246 A1
- Document ID: US20030083246A1
- Status: Published application
- Kind: A1
- Application number: 09/898,195
- Filed: 2001-07-02
- Published: 2003-05-01
- Earliest claimed: 2000-07-03
- Assignees: Bristol-Myers Squibb Company
- Inventors: Robert Cohen; Suzette Carr; David Hagerty; Robert J. Peach; Jean-Claude Becker
- Web page: https://patentgrep.com/patent/US20030083246A1

## CPC

- A61K 38/20: Interleukins [IL]
- A61K 38/13: Cyclosporins
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 21/04: for myasthenia gravis
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/70521: {CD28, CD152}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compositions and methods for treating rheumatic disease by administering to a subject, soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands.

## Claims

### Claim 1

A method for treating a rheumatic disease comprising administering to a subject an effective amount of a soluble CTLA4 mutant molecule that binds a B7 molecule.

### Claim 2 (depends on 1)

The method of claim 1 further comprising administering to a subject an effective amount of at least one immunosuppressive agent, wherein the immunosuppressive agent is selected from the group consisting of corticosteroids, nonsteroidal antiinflammatory drugs, cyclosporin prednisone, azathioprine, methotrexate, TNFα blockers or antagonists, infliximab, any biological agent targeting an inflammatory cytokine, hydroxychloroquine, sulphasalazopryine, gold salts, etanercept, and anakinra.

### Claim 3 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule inhibits the B7 molecule from binding CTLA4 and/or CD28 on T cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule interferes with T-cell/B7-positive cell interactions.

### Claim 5 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule comprises a mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with any other amino acid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the soluble CTLA4 mutant molecule is a L104EIg beginning with methionine at position +1 through lysine at position +357 as shown in FIG. 18.

### Claim 7 (depends on 5)

The method of claim 5, wherein the soluble CTLA4 mutant molecule is a L104EIg beginning with alanine at position −1 through lysine at position +357 as shown in FIG. 18.

### Claim 8 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule comprises a first mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid, and a second mutation at
a. position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with any other amino acid,
b. position +105 of CTLA4, wherein glycine at position +105 as shown in FIG. 23 is substituted with any other amino acid,
c. position +25 of CTLA4, wherein serine at position +25 as shown in FIG. 23 is substituted with any other amino acid, or
d. position +30 of CTLA4, wherein threonine at position +30 as shown in FIG. 23 is substituted with any other amino acid.

### Claim 9 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule is
a. L104EA29YIg, beginning with methionine at position +1 and ending with lysine at position +357 as shown in FIG. 19,
b. L104EA29LIg, beginning with methionine at position +1 and ending with lysine at position +357 as shown in FIG. 20,
c. L104EA29TIg, beginning with methionine at position +1 and ending with lysine at position +357 as shown in FIG. 21, or
d. L104EA29WIg, beginning with methionine at position +1 and ending with lysine at position +357 as shown in FIG. 22.

### Claim 10 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule is
a. L104EA29YIg, beginning with alanine at position −1 and ending with lysine at position +357 as shown in FIG. 19.
b. L104EA29LIg, beginning with alanine at position −1 and ending with lysine at position +357 as shown in FIG. 20,
c. L104EA29TIg, beginning with alanine at position −1 and ending with lysine at position +357 as shown in FIG. 21, or
d. L104EA29WIg, beginning with alanine at position −1 and ending with lysine at position +357 as shown in FIG. 22.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, wherein L104EA29YIg is encoded by a DNA sequence designated ATCC PTA-2104.

### Claim 12 (depends on 1)

The method of claim 1, wherein the soluble CTLA4 mutant molecule comprises a mutation at
a. position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid,
b. position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with tyrosine, and
c. position +25 of CTLA4, wherein serine at position +25 as shown in FIG. 23 is substituted with any other amino acid.

### Claim 13

A method for treating rheumatic disease comprising administering to a subject an effective amount of a soluble CTLA4 mutant molecule that binds a B7 molecule, wherein the soluble CTLA4 mutant molecule comprises a mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid and a mutation at position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with tyrosine.

### Claim 14 (depends on 13)

The method of claim 13, wherein the soluble CTLA4 mutant molecule is L104EA29YIg.

### Claim 15 (depends on 14)

The method of claim 14, wherein L104EA29YIg begins with methionine at position +1 and ending with lysine at position +357 as shown FIG. 19.

### Claim 16 (depends on 14)

The method of claim 14, wherein L104EA29YIg begins with alanine at position −1 and ending with lysine at position +357 as shown FIG. 19

### Claim 17 (depends on 1, 13)

The method of claim 1 or 13, wherein the rheumatic disease is rheumatoid arthritis.

### Claim 18 (depends on 1, 13)

A method for alleviating a symptom associated with a rheumatic disease selected from the group consisting of joint swelling, pain, tenderness, morning stiffness, structural damage, an elevated level of serum C-reactive protein, an elevated level of soluble IL-2r, an elevated level of soluble ICAM-1, an elevated level of soluble E-selectin and an elevated erythrocyte sedimentation rate, by treating a subject suffering from a rheumatic disease by the method of claim 1 or 13.

### Claim 19 (depends on 1, 13)

The method of claims 1 or 13, wherein administration of the soluble CTLA4 mutant molecule is effected locally or systemically.

### Claim 20 (depends on 19)

The method of claim 19, wherein administration is selected from the group consisting of intravenous, intramuscular, subcutaneous, implantable pump, continuous infusion, gene therapy, lipososomal and oral administration.

### Claim 21 (depends on 1, 13)

The method of claims 1 or 13, wherein the effective amount of soluble CTLA4 mutant molecule is between about 0.5 through 100 mg/kg weight of the subject.

### Claim 22 (depends on 21)

The method of claim 21, wherein the effective amount of soluble CTLA4 mutant molecule is 0.5 mg/kg weight of the subject.

### Claim 23 (depends on 21)

The method of claim 21, wherein the effective amount of soluble CTLA4 mutant molecule is 2 mg/kg weight of the subject.

### Claim 24 (depends on 21)

The method of claim 21, wherein the effective amount of soluble CTLA4 mutant molecule is 10 mg/kg weight of the subject.

### Claim 25 (depends on 1, 13)

The method of claims 1 or 13, wherein the subject is selected from the group consisting of human, monkey, ape, dog, cat, cow, horse, rabbit, mouse, and rat.

### Claim 26

A pharmaceutical composition for treating a rheumatic disease comprising a pharmaceutically acceptable carrier and a soluble CTLA4 mutant molecule.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the soluble CTLA4 mutant molecule comprises a mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid and a mutation at position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with tyrosine.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the soluble CTLA4 mutant molecule is L104EA29YIg.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the L104EA29YIg begins with methionine at position +1 and ending with lysine at position +357 as shown FIG. 19.

### Claim 30 (depends on 28)

The pharmaceutical composition of claim 28, wherein the L104EA29YIg begins with alanine at position −1 and ending with lysine at position +357 as shown FIG. 19.

### Claim 31 (depends on 26)

The pharmaceutical composition of claim 26, wherein the pharmaceutically acceptable carrier is selected ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, phosphate buffered saline solution, water, emulsions, salts or electrolytes, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sterile solutions, tablets, excipients, sucrose, glucose, maltose, flavor and color additives, lipid compositions and polymeric compositions.

### Claim 32 (depends on 1, 13)

A method for inducing a pathophysiological change associated with a rheumatic disease by treating a subject suffering from the rheumatic disease by the method of claim 1 or 13.

### Claim 33 (depends on 32)

The method of claim 32, wherein the pathophysiological change associated with rheumatic disease is reduced structural damage.

### Claim 34

A kit for treating rheumatoid arthritis, said kit comprising an effective amount of a soluble CTLA4 mutant molecule that binds to a B7 molecule.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the soluble CTLA4 mutant molecule comprises a mutation at position +104 of CTLA4, wherein leucine at position +104 as shown in FIG. 23 is substituted with glutamic acid and a mutation at position +29 of CTLA4, wherein alanine at position +29 as shown in FIG. 23 is substituted with tyrosine.

### Claim 36 (depends on 35)

The kit of claim 35, wherein the soluble CTLA4 mutant is L104EA29YIg.

### Claim 37 (depends on 36)

The kit of claim 36, wherein L104EA29YIg begins with methionine at position +1 and ending with lysine at position +357 as shown FIG. 19.

### Claim 38 (depends on 36)

The kit of claim 36, wherein L104EA29YIg begins with alanine at position −1 and ending with lysine at position +357 as shown FIG. 19.

### Claim 39 (depends on 34)

The kit of claim 34 further comprising an effective amount of an immunosuppressive agent, wherein the immunosuppressive agent is selected from the group consisting of corticosteroids, nonsteroidal antiinflammatory drugs, cyclosporin prednisone, azathioprine, methotrexate, TNFα blockers or antagonists, infliximab, any biological agent targeting an inflammatory cytokine, hydroxychloroquine, sulphasalazopryine, gold salts, etanercept, and anakinra.
